Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.
PR Newswire —
DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Mwyngil Therapeutics Inc., a biopharmaceutical company dedicated to developing first-in-class and best-in-class small-molecule therapies targeting cardiovascular, metabolic, and chronic inflammatory and immune diseases, today announced the...